Evolent Health Yönetim

Yönetim kriter kontrolleri 2/4

Evolent Health CEO'su Seth Blackley, Jan2011 tarihinde atandı, in görev süresi 13.83 yıldır. in toplam yıllık tazminatı $ 8.93M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.8% maaş ve 91.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.27% ine doğrudan sahiptir ve bu hisseler € 4.43M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.7 yıl ve 4.4 yıldır.

Anahtar bilgiler

Seth Blackley

İcra Kurulu Başkanı

US$8.9m

Toplam tazminat

CEO maaş yüzdesi	8.8%
CEO görev süresi	13.8yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	3.7yrs
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Seth Blackley'un ücretlendirmesi Evolent Health'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$104m
Jun 30 2024	n/a	n/a	-US$106m
Mar 31 2024	n/a	n/a	-US$141m
Dec 31 2023	US$9m	US$783k	-US$142m
Sep 30 2023	n/a	n/a	-US$112m
Jun 30 2023	n/a	n/a	-US$77m
Mar 31 2023	n/a	n/a	-US$40m
Dec 31 2022	US$8m	US$683k	-US$19m
Sep 30 2022	n/a	n/a	-US$4m
Jun 30 2022	n/a	n/a	-US$19m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$7m	US$600k	-US$30m
Sep 30 2021	n/a	n/a	-US$45m
Jun 30 2021	n/a	n/a	-US$68m
Mar 31 2021	n/a	n/a	-US$261m
Dec 31 2020	US$4m	US$438k	-US$328m
Sep 30 2020	n/a	n/a	-US$515m
Jun 30 2020	n/a	n/a	-US$504m
Mar 31 2020	n/a	n/a	-US$334m
Dec 31 2019	US$3m	US$400k	-US$304m
Sep 30 2019	n/a	n/a	-US$121m
Jun 30 2019	n/a	n/a	-US$107m
Mar 31 2019	n/a	n/a	-US$86m
Dec 31 2018	US$2m	US$400k	-US$53m
Sep 30 2018	n/a	n/a	-US$49m
Jun 30 2018	n/a	n/a	-US$49m
Mar 31 2018	n/a	n/a	-US$56m
Dec 31 2017	US$2m	US$400k	-US$61m

Tazminat ve Piyasa: Seth 'nin toplam tazminatı ($USD 8.93M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.64M ).

Tazminat ve Kazançlar: Seth şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Seth Blackley (45 yo)

13.8yrs

Görev süresi

US$8,931,188

Tazminat

Mr. Seth Barrie Blackley serves as Chief Executive Officer at Evolent Health, Inc. since October 1, 2020. He serves as President of True Health Indiana, Inc. (True Health Indiana). Mr. Blackley co-founded...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Seth Blackley	Co-Founder	13.8yrs	US$8.93m	0.27% € 4.4m
Dan McCarthy	President	2.2yrs	US$5.76m	0.16% € 2.7m
John Johnson	Chief Financial Officer	5.3yrs	US$3.53m	0.15% € 2.4m
Emily Rafferty	Chief Operating Officer	1.3yrs	US$2.69m	0.055% € 903.4k
Jonathan Weinberg	Chief Legal Officer	10.8yrs	US$2.01m	0.11% € 1.8m
Aammaad Shams	Chief Accounting Officer	4.4yrs	US$634.88k	0.020% € 325.2k
Mark Mannion	Senior Vice President of Corporate Finance	less than a year	Veri yok	Veri yok
Robert Cruz	Chief Technology Officer	no data	Veri yok	Veri yok
Jessica White	Chief Information Officer	less than a year	Veri yok	Veri yok
Seth Frank	Vice President of Investor Relations	2.9yrs	Veri yok	Veri yok
John Tam	Chief Strategy Officer	12.8yrs	Veri yok	Veri yok
Scott Pritchard	President of Performance Suite	no data	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

40.5yo

Ortalama Yaş

Deneyimli Yönetim: 9EH 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Seth Blackley	Co-Founder	6.6yrs	US$8.93m	0.27% € 4.4m
Peter Grua	Independent Director	4.8yrs	US$260.25k	0.036% € 597.3k
Richard Jelinek	Independent Director	1.4yrs	US$245.50k	0.0059% € 96.2k
Russell Glass	Independent Director	less than a year	Veri yok	0.0053% € 86.2k
Cheryl Scott	Independent Chairperson of the Board & Lead Independent Director	9yrs	US$347.75k	0.038% € 624.0k
Diane Holder	Independent Director	13.3yrs	US$265.25k	0.048% € 784.9k
Mary Duffy	Independent Director	7.2yrs	US$255.25k	0.035% € 574.2k
Kim Keck	Independent Director	3.8yrs	US$265.25k	0.018% € 303.1k
Craig Barbarosh	Independent Director	3.9yrs	US$257.50k	0.019% € 317.0k
Toyin Ajayi	Independent Director	1.3yrs	US$195.83k	0% € 0

4.4yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 9EH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

Evolent Health Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Evolent Health, Inc., Annual General Meeting, Jun 06, 2024

High number of new directors

Evolent Health, Inc. Appoints Toyin Ajayi to Its Board of Directors

Evolent Health, Inc. Announces Executive Changes

Evolent Health, Inc., Annual General Meeting, Jun 08, 2023

High number of new directors

Recent updates

Third quarter 2024 earnings released: US$0.27 loss per share (vs US$0.30 loss in 3Q 2023)

Evolent Health, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024 and Reiterates Earnings Guidance for the Full Year 2024

Second quarter 2024 earnings released: EPS: US$0.014 (vs US$0.37 loss in 2Q 2023)

Evolent Health, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2024 and for the Full Year Ending December 31, 2024

Evolent Health, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Evolent Health, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Raises Earnings Guidance for the Full Year Full Year Ending December 31, 2024

First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 1Q 2023)

Evolent Health, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: US$1.28 loss per share (vs US$0.20 loss in FY 2022)

Evolent Health, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Evolent Health, Inc., Annual General Meeting, Jun 06, 2024

Evolent Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Forecast to breakeven in 2024

Evolent Health, Inc. Provides Earnings Guidance for the Fourth Quarter Ending December 31, 2023 and Full Year 2023

Third quarter 2023 earnings released: US$0.30 loss per share (vs US$0.022 profit in 3Q 2022)

Evolent Health, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Insider selling

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.046 loss in 2Q 2022)

Evolent Health, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2023 and Reiterates Earnings Guidance for the Full Year Ending December 31, 2023

High number of new directors

Evolent Health, Inc. Appoints Toyin Ajayi to Its Board of Directors

Evolent Health, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Evolent Health, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: US$0.20 loss per share (vs US$0.35 loss in FY 2021)

Evolent Health, Inc., Annual General Meeting, Jun 08, 2023

Evolent Health, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Evolent Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.022 (vs US$0.15 loss in 3Q 2021)

Evolent Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Evolent Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Evolent Health, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Saxena White P.A. Announces Proposed Settlement in Evolent Health, Inc. Securities Litigation

Evolent Health, Inc. Announces Executive Changes

Lead Independent Director recently sold €113k worth of stock

High number of new directors

Chief Financial Officer recently sold €618k worth of stock

Second quarter 2022 earnings released: US$0.046 loss per share (vs US$0.11 loss in 2Q 2021)

Evolent Health, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2022 and for the Year Ending December 31, 2022

First quarter 2022 earnings released: US$0.06 loss per share (vs US$0.13 loss in 1Q 2021)

Evolent Health, Inc. Provides Unaudited Earnings Guidance for the Second Quarter Ending June 30, 2022 and Full Year Ending December 31, 2022

Evolent Health, Inc. to Report Q1, 2022 Results on May 04, 2022

Evolent Health, Inc. Announces Changes to Board of Directors, Adds Michael Mentesana and Elevates Frank Williams to Chairman Role

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Forecast breakeven date pushed back to 2024

Evolent Health, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2022 and Full Year Ending December 31, 2022

Evolent Health, Inc., Annual General Meeting, Jun 09, 2022

High number of new directors

Forecast to breakeven in 2023

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.44 loss in 3Q 2020)

Evolent Health, Inc. (NYSE:EVH) entered into a definitive agreement to acquire Vital Decisions, LLC from Windrose Health Investors III, L.P., fund managed by WindRose Health Investors, LLC for $130 million.

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$2.39 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.93 loss in 1Q 2020)

Evolent Health, Inc. Provides Revenue Guidance for the Second Quarter and Full Year of Fiscal Year Ending December 31, 2021

Full year 2020 earnings released: US$3.94 loss per share (vs US$3.67 loss in FY 2019)

Revenue beats expectations

New 90-day high: €16.90

Evolent Health, Inc., Annual General Meeting, Jun 10, 2021

Evolent Health, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €15.40

Evolent Health, Inc. Announces Executive Appointments

New 90-day high: €13.90

Evolent Health, Inc. Appoints Craig Barbarosh to Board of Directors as A Class III Director and to the Strategy Committee and Compensation Committee

New 90-day high: €12.80

New 90-day high: €12.20

Revenue beats expectations

Third quarter 2020 earnings released: US$0.44 loss per share

Evolent Health's Subsidiary New Century Health to Support Florida Blue Medicare with Comprehensive Oncology Management Services